Skip to main content

Table 2 Association of clinicopathologic parameters with Her2 and Ki-67 expression using multivariable-adjusted logistic regression

From: Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study

Variable

Her2

Ki-67

OR (95% CI)

P

OR (95% CI)

P

Sex

 Male

1 (reference)

 

1 (reference)

 

 Female

0.72 (0.36–1.46)

0.360

0.75 (0.39–1.47)

0.405

 Age (as continuous)

1.01 (0.97–1.04)

0.705

1.03 (1.00–1.06)

0.092

Tumor location

 Gastric cardia and fundus

1 (reference)

 

1 (reference)

 

 Gastric body

1.59 (0.75–3.37)

0.544

1.51 (0.72–3.17)

0.983

 Gastric antrum and pylorus

1.05 (0.51–2.20)

0.647

1.05 (0.52–2.13)

0.367

Tumor differentiation

 Well/moderate

1 (reference)

 

1 (reference)

 

 Poor/undifferentiated

0.25 (0.12–0.53)

 < 0.001

1.10 (0.53–2.26)

0.806

Neural invasion

 No

1 (reference)

 

1 (reference)

 

 Yes

2.35 (1.01–5.48)

0.048

0.75 (0.33–1.70)

0.487

Tumor thrombosis

 No

1 (reference)

 

1 (reference)

 

 Yes

1.24 (0.56–2.75)

0.601

0.96 (0.44–2.08)

0.917

 Tumor length (as continuous)

1.09 (0.93–1.29)

0.276

0.97 (0.83–1.13)

0.700

pT stage

 1

1 (reference)

 

1 (reference)

 

 2

1.39 (0.41–4.67)

0.134

0.94 (0.27–3.20)

0.559

 3–4

0.26 (0.08–0.85)

0.001

0.50 (0.16–1.54)

0.128

pN stage

 0

1 (reference)

 

1 (reference)

 

 1

2.69 (1.09–6.62)

0.030

1.42 (0.61–3.30)

0.673

 2

2.71 (1.14–6.43)

0.027

1.20 (0.54–2.66)

0.867

 3

2.83 (1.17–6.87)

0.016

1.46 (0.65–3.31)

0.559

  1. Her2 and Ki-67 are in the sequential order of −, +, ++ , and +++. The positivity degree of Her2 expression follows the National Comprehensive Cancer Network (NCCN) Guidelines (https://www.nccn.org): − means “no reactivity or membranous reactivity in < 10% of cancer cells”; + means “faint or barely perceptible membranous reactivity in ≥ 10% of cancer cells; cells are reactive only in part of their membrane”; ++ means “weak to moderate complete, basolateral or lateral membranous reactivity in ≥ 10% of cancer cells”; +++ means “strong complete, basolateral, or lateral membranous reactivity in ≥ 10% of cancer cells”. – or + expression indicates a negative result, and +++ expression suggests a positive finding. In case of ++ expression by immunohistochemistry, in situ hybridization was further performed, and cases with an average Her2 copy number ≥ 6.0 signals/cell are considered positive. For Ki-67, − means very low proliferation activity with proportion of Ki-67-positive cells < 25%; + means low proliferation activity with proportion of Ki-67-positive cells 25–50%; ++ means moderate proliferation activity with proportion of Ki-67-positive cells 50–75%; +++ means high proliferation activity with proportion of Ki-67-positive cells > 75%. A section was regarded negative in Ki-67 expression with < 50% positive cells, and positive with ≥ 50% positive cells. Significant associations are shown in italics
  2. pT stage pathological tumor stage, pN stage pathological node stage, Her2 human epidermal growth factor receptor 2; OR odds ratio, CI confidence interval